The UK clinical trials sector has long been recognized as a global powerhouse, but in recent years, it has faced intensifying pressure. While traditional heavyweights like the US and rapidly emerging leaders like China often dominate the conversation, European rivals much closer to home are capturing the industry's attention. Chief among them is the Catalonia region of Spain, which has rapidly evolved into a premier destination for pharmaceutical research.
At the 13th annual Outsourcing in Clinical Trials (OCT) UK & Ireland conference in London on 9-10 June 2026, as reported by Clinical Trials Arena, industry experts and government officials gathered to discuss a critical question: How can Britain differentiate itself, attract more commercial sponsors, and reclaim its competitive edge? For many attendees, the answer involves taking a page straight out of Spain's playbook.
The Catalonia Advantage: A Hub for Commercial Sponsors
In a standout panel session, Suki Balendra, Director of Strategic Partnerships at Paddington Life Sciences, shared observations from her recent visit to Catalonia-a region that currently hosts over 1,600 biotech companies. A pivotal factor underpinning Catalonia’s success is its remarkable ability to attract commercial sponsors.
According to Balendra, approximately three-quarters (75%) of the clinical studies conducted in the Catalonia region are commercially funded. This stands in stark contrast to the UK, where only about one-fifth (20%) of studies are commercially run. "It's truly impressive," Balendra noted. She highlighted that Catalonia’s success stems from a highly cohesive system characterized by strong speciality expertise, excellent infrastructure, and a deliberate strategy to fortify its academic base precisely to support commercial endeavors. Conversely, the British healthcare ecosystem has often been criticized for its siloing and fragmentation.
Addressing the NHS Bottleneck
To bridge the gap with regions like Catalonia, Maria Koufali, Director of Life Sciences at the UK's National Institute for Health and Care Research (NIHR), emphasized that the nation must foster deeper collaboration to drive recruitment growth. A major priority is conducting a higher volume of commercial trials directly within NHS trusts.
Alex Churchill, Deputy Director of Clinical Trials Policy at the Department of Health and Social Care (DHSC), echoed this sentiment. Churchill suggested that strategic use of funds from the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) agreement could be instrumental in enrolling more UK patients into commercial trials, a necessary step if Britain hopes to stay competitive with rising stars like Spain.
Regulatory Agility: The MHRA's Revised Approach
Attracting commercial investment requires more than just patient recruitment; it demands regulatory agility. The UK government is already advancing frameworks like the Life Sciences Sector Plan and the National Healthtech Access Programme (NHAP), but the Medicines and Healthcare products Regulatory Agency (MHRA) is also undergoing a fundamental shift in its approach.
Puja Myles, Director of the MHRA's Clinical Practice Research Datalink (CPRD), outlined the agency's renewed focus on building a "proportionate, streamlined, agile, and flexible framework," acknowledging that some international regulators have adopted less risk-averse postures that are highly attractive to sponsors.
A key milestone in this effort is the MHRA's ambitious 60-day target review time for new clinical trials evaluating investigational medicines-a benchmark that Myles states has already prompted "incredible progress." Furthermore, much like its regulatory peers in the US, the MHRA is incorporating artificial intelligence (AI) into its daily workflows to extract key information from applications, streamlining the administrative burden, though AI is not currently used to guide the actual scientific review process.
Transparency and the 150-Day Benchmark
The NIHR is also aggressively pursuing initiatives to make the UK more appealing to global sponsors. NIHR CEO Lucy Chappell highlighted the organization's new 150-day trial setup benchmark and a push for "radical transparency" of data. Additionally, the NIHR is focused on systematically reducing barriers to ensure patients from all socioeconomic backgrounds can participate in research, specifically targeting "upstream treatment" rather than waiting for end-of-life interventions.
As the global race for clinical trial supremacy accelerates, the UK possesses the scientific pedigree to lead. By learning from cohesive, commercially focused ecosystems like Catalonia, and aggressively streamlining its regulatory and recruitment pathways, Britain is laying the groundwork for a robust and highly competitive future in life sciences research.
Frequently Asked Questions
What is the "Catalonia blueprint"?
It is shorthand for the lessons speakers drew from Catalonia. About three-quarters of studies there are commercial, against about one-fifth in the UK, supported by what Suki Balendra described as a cohesive system, specialty expertise, infrastructure and a strong academic base.
Is the UK adopting Spain's model?
No formal plan to copy Catalonia was announced. Speakers pointed to it as an example while describing UK measures such as the MHRA's 60-day review target for new trial applications and the NIHR's 150-day set-up benchmark.
How do clinical trials benefit the local NHS?
They provide patients with early access to cutting-edge treatments, generate research income, and support high-value clinical specialist employment.
Correction, 2 November 2026: We added the conference dates and source, corrected a reference to the US FDA, removed a duplicated FAQ and replaced FAQ answers that described a Catalan model and a UK adoption plan that no source describes.
